Quantum Genomics SA   Report issue

For profit Phase 2 Phase 3
Founded: Paris France (2006)

Organization Overview

First Clinical Trial
2012
NCT01900171
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

AHA Comprehensive Hypertension Center | Quantum Genomics SA

Active Ingredients

Drugs in Phase 3 Trials (1)

firibastat (10 trials)

Drugs in Phase 2 Trials (1)

ramipril (altace) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Essential Hypertension (Phase 2)

Heart Failure (Phase 2)

Hypertension (Phase 3)

Infarction (Phase 2)

Myocardial Infarction (Phase 2)

Overweight (Phase 2)

Ventricular Dysfunction (Phase 2)

Ventricular Dysfunction, Left (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 2